Q3 2025 saw a 2.8% sales decline due to low stock and price pressure, with gross margin dropping to 59.8%. Cost reductions and lower return rates did not offset lower sales, resulting in negative EBITDA. Ongoing assortment changes and expansion into new markets are expected to drive recovery.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.